Last reviewed · How we verify

Jina Pharmaceuticals Inc. — Portfolio Competitive Intelligence Brief

Jina Pharmaceuticals Inc. pipeline: 0 marketed, 0 filed, 2 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Conventional paclitaxel or Taxol Conventional paclitaxel or Taxol phase 3 Taxane; microtubule stabilizer β-tubulin Oncology
Paclitaxel Lipid Suspension Paclitaxel Lipid Suspension phase 3 Taxane Microtubules Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Akeso · 2 shared drug classes
  2. Sanofi · 2 shared drug classes
  3. Barts & The London NHS Trust · 1 shared drug class
  4. Athenex, Inc. · 1 shared drug class
  5. Bio-Thera Solutions · 1 shared drug class
  6. BeyondSpring Pharmaceuticals Inc. · 1 shared drug class
  7. Aravive, Inc. · 1 shared drug class
  8. Air Force Military Medical University, China · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Jina Pharmaceuticals Inc.:

Cite this brief

Drug Landscape (2026). Jina Pharmaceuticals Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/jina-pharmaceuticals-inc. Accessed 2026-05-16.

Related